X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs VENUS REMEDIES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA VENUS REMEDIES ABBOTT INDIA/
VENUS REMEDIES
 
P/E (TTM) x 35.9 -3.4 - View Chart
P/BV x 9.2 0.1 7,206.4% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ABBOTT INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
VENUS REMEDIES
Mar-18
ABBOTT INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs6,110126 4,853.1%   
Low Rs3,99661 6,540.1%   
Sales per share (Unadj.) Rs1,552.2301.8 514.3%  
Earnings per share (Unadj.) Rs188.8-24.9 -759.2%  
Cash flow per share (Unadj.) Rs196.42.5 7,719.3%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.6293.3 271.6%  
Shares outstanding (eoy) m21.2512.34 172.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.3 1,050.7%   
Avg P/E ratio x26.8-3.8 -711.9%  
P/CF ratio (eoy) x25.736.7 70.0%  
Price / Book Value ratio x6.30.3 1,989.7%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3761,154 9,306.4%   
No. of employees `0003.30.9 359.1%   
Total wages/salary Rs m3,937393 1,001.5%   
Avg. sales/employee Rs Th9,929.34,026.1 246.6%   
Avg. wages/employee Rs Th1,185.1425.0 278.9%   
Avg. net profit/employee Rs Th1,207.7-331.8 -364.0%   
INCOME DATA
Net Sales Rs m32,9853,724 885.7%  
Other income Rs m1,17023 5,199.6%   
Total revenues Rs m34,1553,747 911.6%   
Gross profit Rs m5,245395 1,328.5%  
Depreciation Rs m162338 47.9%   
Interest Rs m38354 10.8%   
Profit before tax Rs m6,215-275 -2,257.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,20332 6,970.6%   
Profit after tax Rs m4,012-307 -1,307.3%  
Gross profit margin %15.910.6 150.0%  
Effective tax rate %35.4-11.5 -308.8%   
Net profit margin %12.2-8.2 -147.6%  
BALANCE SHEET DATA
Current assets Rs m22,6552,638 858.9%   
Current liabilities Rs m6,6812,305 289.9%   
Net working cap to sales %48.48.9 541.5%  
Current ratio x3.41.1 296.3%  
Inventory Days Days65135 47.8%  
Debtors Days Days2946 62.9%  
Net fixed assets Rs m8354,871 17.2%   
Share capital Rs m213123 172.2%   
"Free" reserves Rs m16,7153,496 478.2%   
Net worth Rs m16,9283,619 467.7%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m24,1627,509 321.8%  
Interest coverage x163.70.2 73,412.4%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.40.5 275.2%   
Return on assets %16.80.6 2,655.4%  
Return on equity %23.7-8.5 -279.5%  
Return on capital %36.91.6 2,334.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m3690-   
Fx outflow Rs m3,807517 737.0%   
Net fx Rs m-3,438-517 665.6%   
CASH FLOW
From Operations Rs m1,527514 296.9%  
From Investments Rs m-2,148-123 1,745.2%  
From Financial Activity Rs m-1,024-387 264.6%  
Net Cashflow Rs m-1,6464 -39,181.0%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.2 4,388.9%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 66.4 25.8%  
Shareholders   18,270 20,121 90.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFE  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Dec 11, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - SUVEN LIFE COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS